Navigation Links
Orexigen(R) Therapeutics to Speak at Upcoming Conferences
Date:5/8/2009

SAN DIEGO, May 8 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the following investor conferences:

Bank of America and Merrill Lynch 2009 Health Care Conference

    Date:  Tuesday, May 12, 2009
    Time:  2:40 p.m. - 3:10 p.m. Eastern
    Location: The New York Palace Hotel, New York
    Speaker: Michael Narachi, Chief Executive Officer

Canaccord Adams Diabetes and Obesity Conference

    Date:  Tuesday, May 12, 2009
    Time:  10:40 a.m. - 11:10 a.m. Eastern
    Location: InterContinental The Barclay New York, New York
    Speaker: Graham Cooper, Chief Financial Officer

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the company can be found at http://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
2. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
6. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
7. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
8. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
9. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
10. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
11. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... -- A new therapy developed by researchers at ... of Medicine and Columbia University Medical Center (CUMC) ... cardiovascular disease treatment. , The researchers demonstrated ... therapy could selectively inhibit blood vessel re-narrowing and ... using a balloon catheter to open narrowed or ...
(Date:8/18/2014)... with unprecedented efficiency and data storage may ... built-in electric polarizations to read and write ... popular data-driven technology. But ferroelectrics must first ... a curious habit of "forgetting" stored data. ... Department of Energy,s Brookhaven National Laboratory have ...
(Date:8/18/2014)... Fla. , Aug. 18, 2014 TNI ... biotechnology company pioneering the manufacturing and marketing of innovative ... that the Company is providing a second notice of ... In making the announcement, Noreen Griffin , ... you in advance for your participation in the Annual ...
(Date:8/16/2014)... (PRWEB) August 16, 2014 Firms ... industry provide guidance and advisory services to businesses, ... technical issues. Industry services are highly diverse as ... industry services range from geological and geophysical consulting ... “Consequently, over the past five years, the recovery ...
Breaking Biology Technology:Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4Scientific and Economic Consulting in Canada Industry Market Research Report Now Available from IBISWorld 2Scientific and Economic Consulting in Canada Industry Market Research Report Now Available from IBISWorld 3
... CHICAGO and HOBOKEN, N.J. , Aug. 2 ... Octapharma 25th Anniversary Grants Program is the Rush Hemophilia & ... program supports clinical or pre-clinical research focused on human protein therapies in hematology, ... , , ...
... 2 Tengion Inc. (Nasdaq: TNGN ) ... the position of Chief Financial Officer.  Mr. Davis comes to Tengion after ... to develop improved protein therapeutics. At its peak, Neose employed 200 individuals, ... , , ...
... LAUSANNE , Switzerland , August 2, 2010 ... its Global Films,business to Bilcare AG, one of the world,s leading providers ... . The agreement brings together complimentary capabilities and,synergy,s of two leading global ... ...
Cached Biology Technology:Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 2Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 3Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 4Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 5Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 6Tengion Appoints A. Brian Davis Chief Financial Officer 2Bilcare AG to Acquire INEOS' Global Films Business for EUR100 Million 2Bilcare AG to Acquire INEOS' Global Films Business for EUR100 Million 3
(Date:8/19/2014)... made to decrease China,s increasing caesarean section rate, suggests ... BJOG: An International Journal of Obstetrics and Gynaecology (BJOG) ... delivery rates in the world. Of 16 million babies ... the exact rate is not known, the current Chinese ... caesarean rates ranging from 36% to 58%. However, before ...
(Date:8/19/2014)... HOUSTON, Aug. 19, 2014 To improve students, ... poor grades, the University of Houston (UH) implemented ... for students at risk for failure. , ... Coordinating Board (THECB), the Department of Biology and ... first-year students taking "General Biology" for non-majors and ...
(Date:8/19/2014)... supermarkets to encourage healthier spending habits? A new study ... question by tracking the purchasing records in a supermarket ... the nutritional value of foods for sale. , The ... PhD, and Brian Wansink PhD, author of Slim by ... Hannaford Supermarkets in the Northeastern United States between January ...
Breaking Biology News(10 mins):Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3
... the Younger Dryas interval, which saw a rapid return ... it has been assumed that cooling temperatures and their ... groups. David Meltzer from the Southern Methodist University ... of Arizona in Tucson, USA, suggest otherwise in their ...
... MADISON, WI, April 12, 2010-What do obesity trends ... in Kenya, or alternative soil conservation strategies in Peru ... food and agriculture issues, and represent the world,s interdependence ... to build experiences of a broad and diverse world, ...
... Researchers at the Walter and Eliza Hall Institute have ... the female hormones oestrogen and progesterone, a finding that ... and treatments for breast cancer. The discovery, by ... Bioinformatics divisions, also explains decades of evidence linking breast ...
Cached Biology News:Bringing the world of agriculture to the classroom 2Hormone sensitivity of breast stem cells presents drug target 2
... Immunogen: synthetic peptide corresponding to the third ... dopamine receptor, conjugated to KLH. The immunizing ... and mouse gene. Physical form: Solution ... 0.01% sodium azide. Titertest method: IHC ...
Canine Chondrocytes (CnC) (500,000 cells)...
... Fluorescein 6-Fam, Hex, Tet Cy3, ... Fluorescein Tamra Black Hole Quenchers Molecular ... Tet Tamra, Joe 3 Dabcyl ... New York Double labelled probes are purified ...
... Varioskan is a high performance spectral ... and incubator. With the advanced SkanIt ... reliability for drug discovery assay development. ... fluorescence intensity, time-resolved fluorescence and photometric ...
Biology Products: